Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988006 | 0.97 | — | — | |
| Iodide SCHEMBL4384951 | 0.95 | ALDH1A1 (0.31) | ALDH1A1GAA | |
| Bromide SCHEMBL21777064 | 0.84 | ALDH1A1 (0.33) | ALDH1A1GAA | |
| Bromide SCHEMBL2214550 | 0.84 | ALDH1A1 (0.33) | ALDH1A1GAA | |
| Bromide SCHEMBL28087169 | 0.82 | MEN1 (0.33) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Bromide SCHEMBL28437156 | 0.82 | MEN1 (0.33) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Bromide SCHEMBL193042 | 0.82 | — | — | |
| SCHEMBL173392 | 0.81 | — | — | |
| SCHEMBL6114516 | 0.81 | — | — | |
| Water SCHEMBL4948873 | 0.80 | MEN1 (0.32) | MEN1HSP90AA1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035526-B1 | USE IN OLEDS OF TRANSITION METAL CARBENE COMPLEXES THAT CONTAIN NO CYCLOMETALLATION VIA NON-CARBENES | UDC IRELAND LTD (IE) | 2021-11-17 | — | — | EP | disclosed |
| US-8940904-B2 | Use of transition metal-carbene complexes which do not comprise any cyclometallation via non-carbenes in OLEDs | BASF SE (DE) | 2015-01-27 | — | — | US | disclosed |
| US-8247574-B2 | Use of PT -and PD-BIS- and tetra-carbon complexes with bridged carbon ligands in OLEDs | BASF SE (DE) | 2012-08-21 | — | — | US | disclosed |
| US-20090326237-A1 | USE OF PT-AND PD-BIS-AND TETRA-CARBON COMPLEXES WITH BRIDGED CARBON LIGANDS IN OLEDS | BASF SE (DE) | 2009-12-31 | — | — | US | disclosed |
| EP-2044169-B1 | USE OF PT- AND PD-BIS- AND TETRA-CARBON COMPLEXES WITH BRIDGED CARBON LIGANDS IN OLEDS | BASF SE (DE) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326237-A1 | USE OF PT-AND PD-BIS-AND TETRA-CARBON COMPLEXES WITH BRIDGED CARBON LIGANDS IN OLEDS | PDCD1, PDCD1LG2, CD274 | ACHE 3341/4885ALDH1A1 911/4885GAA 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.